Fabry Disease Registry & Pregnancy Sub-registry
Purpose
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: - To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease; - To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care; - To characterize and describe the Fabry population as a whole; - To evaluate the long-term safety and effectiveness of Fabrazyme® Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.
Condition
- Fabry Disease
Eligibility
- Eligible Ages
- All ages
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Fabry Registry: All patients with a confirmed diagnosis of Fabry disease who have signed the informed consent and patient authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as a documented deficiency in plasma or leukocyte αGAL (alpha-galactosidase) enzyme activity and/or mutation(s) in the gene coding for αGAL. - Fabry Pregnancy Sub-registry: - Eligible women must: - be enrolled in the Fabry Registry. - be pregnant, or have been pregnant with appropriate medical documentation available. - provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.
Exclusion Criteria
Fabry Registry: There are no exclusion criteria. Fabry Pregnancy Sub-registry: There are no exclusion criteria.
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Other
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Patients with Fabry disease | No experimental intervention is given. A patient with Fabry Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. | |
Pregnant women with confirmed diagnosis of Fabry | No experimental intervention is given. Pregnant women with confirmed diagnosis of Fabry that are participating in the Fabry Registry and consented to participate in the Fabry Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with agalsidase beta) and irrespective of the commercial product with which she may be treated. |
Recruiting Locations
Birmingham 4049979, Alabama 4829764 35294
Phoenix 5308655, Arizona 5551752 85013
Tucson 5318313, Arizona 5551752 85724
Little Rock 4119403, Arkansas 4099753 72202
Little Rock 4119403, Arkansas 4099753 72205
Irvine 5359777, California 5332921 92697
Los Angeles 5368361, California 5332921 90027
Los Angeles 5368361, California 5332921 90095
Orange 5379513, California 5332921 92868
Palo Alto 5380748, California 5332921 94305
Sacramento 5389489, California 5332921 95817
San Francisco 5391959, California 5332921
New Haven 4839366, Connecticut 4831725 06520
Washington D.C. 4140963, District of Columbia 4138106 20010
Coral Springs 4151909, Florida 4155751 33065
Gainesville 4156404, Florida 4155751 32610
Jacksonville 4160021, Florida 4155751 32207
Miami 4164138, Florida 4155751 33136
Tampa 4174757, Florida 4155751 33606
Decatur 4191124, Georgia 4197000 30033
Aurora 4883817, Illinois 4896861 80045
Chicago 4887398, Illinois 4896861 60611
Chicago 4887398, Illinois 4896861 60612
Indianapolis 4259418, Indiana 4921868 46202
Iowa City 4862034, Iowa 4862182 52242
Kansas City 4273837, Kansas 4273857 66160
Baton Rouge 4315588, Louisiana 4331987 70809
Portland 4975802, Maine 4971068 04102
Boston 4930956, Massachusetts 6254926 02114
Boston 4930956, Massachusetts 6254926 02115
Boston 4930956, Massachusetts 6254926 2115
Springfield 4951788, Massachusetts 6254926 01199
Ann Arbor 4984247, Michigan 5001836 48109
Detroit 4990729, Michigan 5001836 48201
Grand Rapids 4994358, Michigan 5001836 49525
Minneapolis 5037649, Minnesota 5037779 55404
Minneapolis 5037649, Minnesota 5037779 55455
Columibia, Missouri 4398678 65212
St Louis 4407066, Missouri 4398678 63110
Omaha 5074472, Nebraska 5073708 68198
Las Vegas 5506956, Nevada 5509151 89109
Hackensack 5098706, New Jersey 5101760 07601
Morristown 5101427, New Jersey 5101760 07962
New Brunswick 5101717, New Jersey 5101760 08901
Paterson 5102466, New Jersey 5101760 07503
Manhasset 5125766, New York 5128638 11030
New York 5128581, New York 5128638 10016
New York 5128581, New York 5128638 10029-7494
New York 5128581, New York 5128638 10029
Syracuse 5140405, New York 5128638 13210
Valhalla 5142090, New York 5128638 10595
Charlotte 4460243, North Carolina 4482348 28232
Durham 4464368, North Carolina 4482348 27710
Cincinnati 4508722, Ohio 5165418
Cleveland 5150529, Ohio 5165418 44106
Cleveland 5150529, Ohio 5165418 44195
Columbus 4509177, Ohio 5165418 43205-2664
Dublin 5152333, Ohio 5165418 43017
Portland 5746545, Oregon 5744337 97239
Danville 5186327, Pennsylvania 6254927 17822
Hershey 5193342, Pennsylvania 6254927 17033
Philadelphia 4560349, Pennsylvania 6254927 19104
Philadelphia 4560349, Pennsylvania 6254927
Pittsburgh 5206379, Pennsylvania 6254927 15224
Greenville 4580543, South Carolina 4597040 29605
Nashville 4644585, Tennessee 4662168 38232
Dallas 4684888, Texas 4736286 75226
Fort Worth 4691930, Texas 4736286 76104
Salt Lake City 5780993, Utah 5549030 84132
Fairfax 4758023, Virginia 6254928 22030
Seattle 5809844, Washington 5815135 98105
Seattle 5809844, Washington 5815135 98195
Tacoma 5812944, Washington 5815135 98415
Milwaukee 5263045, Wisconsin 5279468 53226
More Details
- NCT ID
- NCT00196742
- Status
- Recruiting
- Sponsor
- Genzyme, a Sanofi Company